The stock zoomed to a high of Rs 192. It finally ended up 10.5% at Rs 185. A total of 19,684 shares were traded on the BSE today.
Updated at 1414 hrs
Venus Remedies opened flat at Rs 168, it touched a low of Rs 160. However, the stock soon zoomed to a high of Rs 182 on news that DCGI has given it approval to conduct Phase I trials of cancer related drug.
The stock is now trading at Rs 175, up 7%. The counter has clocked a volume of 6,539 shares so far on the BSE.
According to a release issued by the company to the BSE, Venus Remedies has received its first permission to conduct the Phase 1 clinical trials to investigate New Drug application of VRP 1620 from Drugs Controller General of India (DCGI). This VRP 1620 molecule will help to detect cancer.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app